Rituximab
Showing 1 - 25 of 2,665
Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular
Not yet recruiting
- Nodular Lymphocyte Predominant Hodgkin Lymphoma
- +2 more
- Biopsy
- +9 more
- (no location specified)
Jun 1, 2023
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum
Not yet recruiting
- Neuromyelitis Optica Spectrum Disorders
- (no location specified)
Sep 29, 2023
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial
Not yet recruiting
- Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
- Polymorphic Post-Transplant Lymphoproliferative Disorder
- Biopsy
- +5 more
-
New Brunswick, New Jersey
- +2 more
Mar 23, 2023
Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)
Not yet recruiting
- Relapsed/Refractory B-Cell Lymphoma
- FT522
- +4 more
- (no location specified)
Jul 10, 2023
Post-transplant Lymphoproliferative Disorder Trial in Saint Louis (Polatuzumab vedotin, Rituximab, CHP)
Not yet recruiting
- Post-transplant Lymphoproliferative Disorder
- Polatuzumab vedotin
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Sep 9, 2023
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,
Active, not recruiting
- Prolymphocytic Leukemia
- +2 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)
Not yet recruiting
- Lymphoma, Mantle-Cell
- Zanubrutinib
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Nov 14, 2023
Primary Ocular Adnexal MALT Lymphoma Trial (Rituximab, Involved Site Radiation Therapy)
Not yet recruiting
- Primary Ocular Adnexal MALT Lymphoma
- Rituximab
- Involved Site Radiation Therapy
- (no location specified)
Sep 26, 2023
Nephrotic Syndrome in Children Trial in Chongqing (Rituximab, Mycophenolate Mofetil)
Recruiting
- Nephrotic Syndrome in Children
- Rituximab
- Mycophenolate Mofetil
-
Chongqing, Chongqing, ChinaChildren's Hospital of Chongqing Medical University
May 3, 2023
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1
Active, not recruiting
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- +3 more
- Clinical Observation
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)
Not yet recruiting
- Mantle-cell Lymphoma
- Polatuzumab, bendamustin und rituximab
- (no location specified)
May 11, 2023
Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +
Not yet recruiting
- Marginal Zone Lymphoma
- Mosunetuzumab + Lenalidomide
- +3 more
- (no location specified)
Aug 16, 2023
DLBCL Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Jul 11, 2023
Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)
Not yet recruiting
- Splenic Marginal Zone Lymphoma
- Rituximab
- Zanubrutinib
-
Aarhus, Denmark
- +4 more
Feb 17, 2023
OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)
Not yet recruiting
- OR Regimen Refractory Marginal Zone Lymphoma
- obrutinib, rituximab
- (no location specified)
Nov 12, 2023
Myasthenia Gravis, Generalized Trial in Roma (Rituximab, Placebo)
Recruiting
- Myasthenia Gravis, Generalized
- Rituximab
- Placebo
-
Roma, ItalyPoliclinico A. Gemelli IRCCS
May 25, 2023
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann
Active, not recruiting
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- +11 more
- Ibrutinib
- +4 more
-
Washington, District of Columbia
- +6 more
Feb 2, 2023
CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Chemotherapy)
Not yet recruiting
- CNS Lymphoma
- Orelabrutinib
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 22, 2023
Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)
Not yet recruiting
- Mantle Cell Lymphoma Refractory
- Ibrutinib
- +3 more
- (no location specified)
May 16, 2023
Waldenström's Macroglobulinemia Trial (zanubrutinib,bendamustine,rituximab)
Not yet recruiting
- Waldenström's Macroglobulinemia
- (no location specified)
Aug 4, 2023
Selinexor Combined With Lenalidomide and Rituximab in Treatment
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- Selinexor combined with lenalidomide and rituximab
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 20, 2023
Chronic GVHD Trial in Atlanta (Belumosudil, Rituximab)
Not yet recruiting
- Chronic Graft Versus Host Disease
- Belumosudil
- Rituximab
-
Atlanta, GeorgiaNorthside Hospital
Sep 21, 2023
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)
Completed
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
-
Madison, WisconsinUniversity of Wisconsin
Jan 30, 2023